AI Tokens
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Profitability Ratios (Summary)

Return on Sales

Return on Investment

Gilead Sciences Inc., profitability ratios (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Return on Sales
Gross profit margin 79.79% 79.15% 79.01% 78.44% 78.31% 78.42% 78.17% 78.15% 75.98% 75.56% 75.62% 75.87% 78.66% 79.27% 78.94% 79.03% 74.31% 75.30% 75.50%
Operating profit margin -7.68% -8.37% 35.46% 34.66% 36.75% 28.03% 28.77% 5.81% 2.92% 9.26% 5.79% 28.24% 30.37% 31.18% 33.03% 27.17% 22.39% 25.78% 26.56%
Net profit margin -12.56% -10.86% 31.51% 29.43% 28.41% 21.98% 20.87% 1.68% 0.45% 3.82% 1.78% 21.03% 21.60% 20.18% 20.87% 17.02% 12.44% 15.22% 16.60%
Return on Investment
Return on equity (ROE) -29.62% -27.39% 39.19% 37.48% 37.65% 32.08% 31.13% 2.48% 0.69% 5.77% 2.77% 24.81% 26.33% 25.92% 26.59% 21.62% 15.82% 20.44% 22.66%
Return on assets (ROA) -7.51% -6.56% 16.38% 14.42% 13.86% 11.33% 10.57% 0.81% 0.23% 1.97% 0.86% 9.12% 9.42% 8.80% 9.02% 7.27% 5.33% 6.58% 7.16%

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The profitability profile is characterized by a stark contrast between stable core production efficiency and highly volatile operational and net earnings. While the cost of goods sold remains well-managed, the company experienced two distinct periods of severe margin contraction, indicating that volatility is driven by operating expenses or non-operating items rather than direct production costs.

Gross Profit Margin
A consistent and resilient trend is observed in the gross profit margin, which maintained a high range between 74.31% and 79.79%. This stability suggests that the core pricing strategy and direct cost structures remained steady throughout the period, concluding with a gradual increase toward the end of 2026.
Operating and Net Profit Margins
These metrics exhibit extreme volatility. Following a period of stability and growth through 2023, a significant collapse occurred throughout 2024, where the operating margin fell as low as 2.92% and the net margin dropped to 0.45%. A strong recovery followed in 2025, with the net profit margin peaking at 31.51% by March 31, 2026. However, a sharp reversal is evident in the final two quarters of the period, with both operating and net margins entering negative territory, reaching -7.68% and -12.56%, respectively.
Return on Equity (ROE)
ROE mirrors the trajectory of net profitability, displaying aggressive swings. After maintaining levels between 15.82% and 26.59% in 2022 and 2023, the ratio plummeted in 2024 to a low of 0.69%. A subsequent surge saw ROE climb to a peak of 39.19% in early 2026, before collapsing to -29.62% by September 30, 2026, indicating a substantial erosion of shareholder value during the final period.
Return on Assets (ROA)
ROA followed the same cyclical pattern as ROE, though at a lower magnitude. The ratio remained healthy between 5.33% and 9.42% during 2022 and 2023, crashed to near-zero levels in 2024 (bottoming at 0.23%), and recovered to a peak of 16.38% in early 2026. The period concluded with a sharp decline to -7.51%, confirming that the volatility is systemic across all bottom-line return metrics.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Gross Profit Margin

Gilead Sciences Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Gross profit on product sales 6,718 6,048 5,501 6,279 5,776 5,553 5,073 5,955 5,941 5,368 5,095 4,980 5,429 5,122 4,905 5,936 5,583 4,696 5,110
Product sales 8,289 7,627 6,946 7,903 7,345 7,054 6,613 7,536 7,515 6,912 6,647 7,070 6,994 6,564 6,306 7,332 6,978 6,138 6,534
Profitability Ratio
Gross profit margin1 79.79% 79.15% 79.01% 78.44% 78.31% 78.42% 78.17% 78.15% 75.98% 75.56% 75.62% 75.87% 78.66% 79.27% 78.94% 79.03% 74.31% 75.30% 75.50%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc. 73.72% 71.48% 70.68% 70.24% 69.74% 70.93% 70.69% 69.99% 67.21% 62.75% 62.28% 62.42% 65.76% 68.91% 69.43% 70.00% 69.62% 70.48% 69.53%
Amgen Inc. 69.41% 67.97% 66.72% 65.75% 64.71% 62.99% 61.48% 59.85% 58.71% 61.56% 64.76% 68.60% 72.35% 72.87% 73.65% 74.17% 73.99% 74.00% 73.30%
Bristol-Myers Squibb Co. 69.24% 70.16% 70.46% 71.08% 69.50% 70.29% 70.47% 71.08% 74.91% 75.38% 75.71% 76.24% 76.54% 77.01% 77.68% 78.04% 78.82% 79.13% 79.62%
Danaher Corp. 58.59% 58.51% 58.94% 59.11% 59.53% 59.66% 59.74% 59.50% 59.37% 59.27% 58.39% 58.74% 58.77% 59.17% 60.22% 60.21% 60.65% 60.77% 60.77%
Eli Lilly & Co. 83.63% 83.40% 82.83% 83.04% 83.03% 82.64% 81.70% 81.31% 80.91% 80.75% 80.16% 79.25% 78.67% 77.77% 77.67% 76.77% 75.61% 75.98% 74.40%
Johnson & Johnson 67.56% 67.91% 67.82% 67.88% 68.08% 67.92% 68.30% 69.07% 69.05% 69.06% 69.20% 68.82% 68.54% 68.06% 67.34% 67.26% 67.43% 67.86% 67.97%
Merck & Co. Inc. 71.75% 72.97% 73.91% 74.80% 77.18% 76.60% 76.42% 76.32% 75.82% 75.25% 74.37% 73.17% 72.86% 72.96% 72.43% 70.63% 70.49% 70.41% 70.72%
Pfizer Inc. 73.38% 73.18% 73.51% 74.33% 73.39% 72.12% 72.28% 71.94% 67.73% 58.18% 58.09% 58.10% 60.97% 69.61% 68.61% 65.77% 65.53% 62.18% 60.35%
Regeneron Pharmaceuticals Inc. 85.77% 84.86% 84.55% 85.35% 85.39% 85.57% 85.79% 86.13% 86.12% 86.16% 86.32% 86.16% 85.96% 86.42% 86.96% 87.18% 85.39% 84.97% 84.65%
Thermo Fisher Scientific Inc. 41.08% 40.80% 40.78% 40.93% 41.27% 41.18% 41.34% 41.28% 40.77% 40.76% 40.40% 39.90% 39.87% 39.75% 40.28% 42.24% 44.42% 46.63% 48.37%
Vertex Pharmaceuticals Inc. 85.53% 86.00% 86.24% 86.24% 86.28% 86.11% 86.03% 86.11% 86.12% 86.45% 86.86% 87.21% 87.80% 87.92% 88.04% 87.90% 88.00% 88.13% 87.95%

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Gross profit margin = 100 × (Gross profit on product salesQ3 2026 + Gross profit on product salesQ2 2026 + Gross profit on product salesQ1 2026 + Gross profit on product salesQ4 2025) ÷ (Product salesQ3 2026 + Product salesQ2 2026 + Product salesQ1 2026 + Product salesQ4 2025)
= 100 × (6,718 + 6,048 + 5,501 + 6,279) ÷ (8,289 + 7,627 + 6,946 + 7,903) = 79.79%

2 Click competitor name to see calculations.


The financial trajectory of product sales and gross profitability demonstrates a sustained long-term expansion, characterized by a consistent increase in both top-line revenue and overall gross profit. While the data exhibits some quarterly volatility, the general trend indicates a strengthening of operational efficiency and pricing stability over the analyzed period.

Revenue and Gross Profit Correlation
Product sales showed a general upward trend, rising from 6,534 million US dollars in March 2022 to 8,289 million US dollars by September 2026. Gross profit on product sales followed a similar trajectory, increasing from 5,110 million US dollars to 6,718 million US dollars. This parallel growth confirms that the expansion in sales volume has been effectively converted into gross profit growth.
Gross Profit Margin Analysis
The gross profit margin exhibited distinct phases of movement. An initial period of fluctuation occurred between March 2022 and June 2024, where the margin varied between a low of 74.31% in September 2022 and a peak of 79.27% in June 2023. Following a brief correction back to the 75% range in early 2024, a steady and consistent upward trend emerged. From September 2024 through September 2026, the margin climbed progressively, culminating in a period high of 79.79%.
Operational Efficiency and Stability
The ability to maintain gross profit margins within a tight band of approximately 74% to 80% across all twenty quarters indicates a highly stable cost of goods sold relative to revenue. The sustained improvement in the margin during the final six quarters of the data set suggests an optimization of production costs or a strategic shift toward a higher-margin product mix.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Operating Profit Margin

Gilead Sciences Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Operating income (loss) 3,462 (10,394) 2,586 1,984 3,327 2,474 2,237 2,452 888 2,644 (4,322) 1,612 2,623 1,665 1,705 2,267 2,837 2,029 197
Product sales 8,289 7,627 6,946 7,903 7,345 7,054 6,613 7,536 7,515 6,912 6,647 7,070 6,994 6,564 6,306 7,332 6,978 6,138 6,534
Profitability Ratio
Operating profit margin1 -7.68% -8.37% 35.46% 34.66% 36.75% 28.03% 28.77% 5.81% 2.92% 9.26% 5.79% 28.24% 30.37% 31.18% 33.03% 27.17% 22.39% 25.78% 26.56%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 32.16% 26.20% 24.41% 24.65% 15.16% 18.80% 17.56% 16.22% 24.89% 22.31% 23.50% 23.49% 27.32% 31.03% 28.49% 31.21% 30.59% 30.33% 32.68%
Amgen Inc. 34.08% 31.51% 29.77% 25.83% 25.14% 24.45% 22.71% 22.66% 19.97% 20.96% 24.72% 29.35% 34.55% 37.50% 36.07% 38.57% 39.31% 38.04% 32.78%
Bristol-Myers Squibb Co. 23.10% 23.83% 20.55% 20.75% 18.86% 16.70% 15.24% -15.50% -14.05% -14.39% -14.30% 16.18% 16.96% 17.29% 18.13% 17.96% 19.04% 18.19% 16.79%
Danaher Corp. 20.38% 20.42% 19.21% 19.09% 19.01% 18.39% 20.26% 20.37% 20.11% 21.22% 21.05% 21.77% 23.83% 25.06% 27.02% 27.61% 27.35% 25.44% 25.23%
Eli Lilly & Co. 40.34% 42.22% 43.63% 40.35% 38.84% 32.37% 28.74% 28.64% 24.81% 23.28% 20.80% 18.92% 18.42% 24.17% 22.45% 24.97% 24.65% 25.50% 25.94%
Johnson & Johnson 24.90% 26.47% 26.39% 26.85% 25.44% 23.67% 23.59% 23.42% 24.42% 25.31% 25.04% 24.90% 25.55% 25.61% 25.21% 24.63% 23.89% 23.47% 23.76%
Merck & Co. Inc. 8.10% 9.58% 18.18% 32.64% 33.73% 30.00% 31.51% 31.03% 21.60% 24.75% 6.93% 3.92% 13.08% 10.34% 27.85% 30.27% 30.66% 33.04% 28.85%
Pfizer Inc. 21.44% 21.70% 22.96% 22.76% 21.85% 23.23% 19.29% 19.51% 9.56% -4.19% -2.08% 2.15% 14.36% 28.13% 34.44% 34.83% 33.59% 30.37% 26.12%
Regeneron Pharmaceuticals Inc. 28.79% 24.74% 24.32% 24.95% 25.89% 27.02% 27.20% 28.10% 28.69% 28.95% 29.40% 30.85% 32.23% 34.20% 35.79% 38.93% 45.45% 48.19% 55.08%
Thermo Fisher Scientific Inc. 17.88% 17.58% 17.46% 17.38% 17.16% 17.13% 17.23% 17.11% 16.93% 17.01% 16.38% 16.00% 15.81% 15.42% 16.29% 18.69% 20.54% 22.51% 23.83%
Vertex Pharmaceuticals Inc. 33.23% 37.95% 38.31% 34.77% 34.06% 34.36% -6.69% -2.11% -2.54% -3.37% 41.16% 38.83% 40.16% 41.72% 43.93% 48.23% 47.72% 48.85% 36.93%

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Operating profit margin = 100 × (Operating income (loss)Q3 2026 + Operating income (loss)Q2 2026 + Operating income (loss)Q1 2026 + Operating income (loss)Q4 2025) ÷ (Product salesQ3 2026 + Product salesQ2 2026 + Product salesQ1 2026 + Product salesQ4 2025)
= 100 × (3,462 + -10,394 + 2,586 + 1,984) ÷ (8,289 + 7,627 + 6,946 + 7,903) = -7.68%

2 Click competitor name to see calculations.


Analysis of the operating profit margin reveals a pattern of significant volatility characterized by periods of high profitability interrupted by sharp, severe contractions. While product sales maintain a general upward trajectory, increasing from approximately $6.5 billion in early 2022 to over $8.2 billion by late 2026, the operating income fluctuates unpredictably, leading to inconsistent margin performance.

Profitability Cycles and Volatility
The operating profit margin experienced a period of relative stability between 2022 and 2023, generally fluctuating between 22% and 33%. However, a significant disruption occurred in the first quarter of 2024, where the margin plummeted to 5.79%, coinciding with an operating loss of $4.3 billion. This downward pressure persisted throughout 2024, with the margin remaining in the single digits for most of the year, reaching a low of 2.92% in September 2024.
Recovery and Peak Performance
A strong recovery phase is evident throughout 2025. The operating profit margin rebounded sharply to 28.77% in March 2025 and peaked at 36.75% in June 2025. This period represents the highest efficiency in operating income generation relative to sales within the observed timeframe, supported by operating incomes reaching $3.3 billion in the third quarter of 2025.
Recent Performance Degradation
Following the peak in 2025 and a sustained margin of 35.46% in March 2026, a severe decline is observed in the second and third quarters of 2026. In June 2026, the operating profit margin shifted to a negative 8.37%, driven by a substantial operating loss of $10.39 billion. Although the operating income returned to positive territory in September 2026, the margin remained negative at -7.68%, indicating that operational costs or one-time charges heavily offset the growth in product sales during this period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Net Profit Margin

Gilead Sciences Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead 2,429 (10,496) 2,021 2,183 3,052 1,960 1,315 1,783 1,253 1,614 (4,170) 1,430 2,180 1,045 1,010 1,640 1,789 1,144 19
Product sales 8,289 7,627 6,946 7,903 7,345 7,054 6,613 7,536 7,515 6,912 6,647 7,070 6,994 6,564 6,306 7,332 6,978 6,138 6,534
Profitability Ratio
Net profit margin1 -12.56% -10.86% 31.51% 29.43% 28.41% 21.98% 20.87% 1.68% 0.45% 3.82% 1.78% 21.03% 21.60% 20.18% 20.87% 17.02% 12.44% 15.22% 16.60%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 15.67% 9.80% 5.79% 6.91% 4.00% 6.45% 7.31% 7.59% 9.22% 9.71% 11.02% 8.95% 11.81% 15.50% 13.37% 20.39% 23.19% 22.04% 22.00%
Amgen Inc. 25.38% 24.11% 21.98% 21.94% 20.31% 19.75% 18.10% 12.77% 13.58% 10.60% 13.35% 24.96% 29.52% 31.52% 31.77% 26.42% 27.88% 26.73% 23.42%
Bristol-Myers Squibb Co. 18.47% 18.87% 15.01% 14.64% 12.57% 10.58% 11.38% -18.53% -15.30% -14.06% -13.50% 17.83% 18.44% 17.62% 15.95% 13.71% 14.29% 14.04% 13.31%
Danaher Corp. 16.91% 15.95% 14.89% 14.71% 14.43% 14.21% 15.81% 16.33% 16.39% 17.83% 18.54% 19.94% 22.89% 22.80% 23.32% 22.91% 21.65% 20.61% 21.32%
Eli Lilly & Co. 31.90% 33.53% 34.99% 31.67% 30.99% 25.91% 22.66% 23.51% 20.48% 18.86% 17.08% 15.36% 15.55% 22.01% 20.54% 21.88% 20.63% 19.58% 20.90%
Johnson & Johnson 16.20% 21.48% 21.83% 28.46% 27.26% 25.00% 24.41% 15.84% 16.74% 43.91% 44.92% 41.28% 39.58% 14.52% 13.77% 18.90% 19.95% 19.21% 20.90%
Merck & Co. Inc. 3.64% 4.77% 13.59% 28.08% 29.63% 25.79% 27.27% 26.68% 19.23% 21.98% 3.76% 0.61% 7.77% 5.34% 22.52% 24.49% 25.88% 29.00% 26.27%
Pfizer Inc. 6.34% 6.80% 11.83% 12.42% 15.65% 16.84% 12.62% 12.62% 7.04% -4.62% -0.55% 3.56% 15.13% 27.38% 31.19% 31.27% 29.81% 28.94% 27.01%
Regeneron Pharmaceuticals Inc. 28.51% 27.86% 29.65% 31.41% 32.13% 31.37% 31.94% 31.07% 33.61% 32.04% 29.45% 30.14% 30.47% 33.93% 33.81% 35.64% 39.17% 39.97% 48.06%
Thermo Fisher Scientific Inc. 14.94% 15.04% 15.15% 15.05% 15.02% 15.23% 15.18% 14.77% 14.48% 14.69% 14.20% 13.99% 13.68% 13.14% 13.75% 15.47% 15.92% 17.37% 18.49%
Vertex Pharmaceuticals Inc. 30.70% 35.00% 35.51% 32.94% 31.35% 31.86% -8.91% -4.86% -4.52% -4.74% 39.46% 36.68% 35.94% 35.40% 35.40% 37.20% 37.62% 38.26% 30.84%

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Net profit margin = 100 × (Net income (loss) attributable to GileadQ3 2026 + Net income (loss) attributable to GileadQ2 2026 + Net income (loss) attributable to GileadQ1 2026 + Net income (loss) attributable to GileadQ4 2025) ÷ (Product salesQ3 2026 + Product salesQ2 2026 + Product salesQ1 2026 + Product salesQ4 2025)
= 100 × (2,429 + -10,496 + 2,021 + 2,183) ÷ (8,289 + 7,627 + 6,946 + 7,903) = -12.56%

2 Click competitor name to see calculations.


The net profit margin exhibits significant volatility over the analyzed period, characterized by distinct cycles of stability, contraction, and expansion. While product sales demonstrate a generally consistent upward trajectory, net income fluctuates sharply, leading to substantial variance in profit margins.

Stability and Incremental Growth (2022-2023)
During 2022, the net profit margin fluctuated between 12.44% and 17.02%. A transition toward higher profitability occurred in 2023, with margins stabilizing and increasing to a range between 20.18% and 21.60%.
Profitability Contraction (2024)
A severe decline in margins is observed throughout 2024. Despite product sales remaining robust, the net profit margin dropped precipitously, reaching a period low of 0.45% in September 2024. This contraction coincides with a significant net loss of 4,170 million US dollars in the first quarter of that year.
Recovery and Peak Performance (2025-Early 2026)
A strong recovery phase began in March 2025, with the net profit margin returning to 20.87%. Margins then experienced a consistent upward trend, peaking at 31.51% by March 2026, marking the highest level of profitability recorded in the sequence.
Severe Reversal (Mid-2026)
The period concludes with a sharp reversal in profitability during the second and third quarters of 2026. The net profit margin transitioned into negative territory, falling to -10.86% in June and further declining to -12.56% by September 2026, driven by a substantial net loss of 10,496 million US dollars in June 2026.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Return on Equity (ROE)

Gilead Sciences Inc., ROE calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead 2,429 (10,496) 2,021 2,183 3,052 1,960 1,315 1,783 1,253 1,614 (4,170) 1,430 2,180 1,045 1,010 1,640 1,789 1,144 19
Total Gilead stockholders’ equity 13,040 11,829 23,515 22,703 21,540 19,674 19,162 19,330 18,475 18,281 17,539 22,833 22,314 21,158 20,997 21,240 21,081 20,236 19,927
Profitability Ratio
ROE1 -29.62% -27.39% 39.19% 37.48% 37.65% 32.08% 31.13% 2.48% 0.69% 5.77% 2.77% 24.81% 26.33% 25.92% 26.59% 21.62% 15.82% 20.44% 22.66%
Benchmarks
ROE, Competitors2
AbbVie Inc. — — — — — — 295.42% 128.66% 84.91% 78.77% 74.85% 46.94% 53.86% 67.50% 57.14% 68.60% 83.83% 86.24% 76.64%
Amgen Inc. 65.43% 74.80% 84.87% 89.06% 72.82% 89.11% 95.59% 69.59% 56.20% 52.83% 74.93% 107.78% 98.82% 117.67% 148.04% 178.97% 187.11% 271.85% 624.78%
Bristol-Myers Squibb Co. 39.49% 41.59% 36.25% 38.19% 32.55% 28.96% 31.16% -54.78% -42.34% -38.44% -37.28% 27.27% 28.57% 24.91% 22.97% 20.37% 20.44% 20.30% 19.79%
Danaher Corp. 8.08% 7.61% 6.97% 6.88% 6.86% 6.52% 7.40% 7.87% 7.59% 8.42% 8.24% 8.91% 11.29% 12.30% 13.47% 14.39% 14.40% 13.63% 13.93%
Eli Lilly & Co. 68.49% 78.84% 81.02% 77.78% 77.38% 75.52% 70.45% 74.62% 58.78% 54.14% 47.91% 48.65% 44.46% 58.73% 50.82% 58.64% 59.91% 66.61% 65.69%
Johnson & Johnson 19.74% 24.76% 25.92% 32.87% 31.69% 28.88% 27.92% 19.68% 20.93% 53.14% 54.95% 51.11% 48.61% 17.37% 17.95% 23.36% 25.68% 24.05% 26.54%
Merck & Co. Inc. 5.46% 7.57% 19.48% 34.70% 36.71% 33.49% 36.07% 36.96% 27.30% 31.52% 5.71% 0.97% 11.17% 8.04% 27.82% 31.57% 34.32% 38.34% 34.68%
Pfizer Inc. 4.53% 5.09% 8.31% 8.99% 10.59% 12.12% 8.73% 9.11% 4.61% -2.96% -0.33% 2.38% 10.81% 21.68% 28.77% 32.79% 32.14% 33.61% 30.29%
Regeneron Pharmaceuticals Inc. 14.38% 13.65% 14.08% 14.41% 14.79% 14.89% 15.31% 15.03% 15.87% 15.32% 14.29% 15.22% 16.03% 17.90% 17.80% 19.14% 25.05% 27.49% 39.84%
Thermo Fisher Scientific Inc. 12.91% 13.23% 13.19% 12.55% 12.88% 13.03% 13.19% 12.78% 12.52% 13.12% 13.26% 12.83% 13.11% 13.08% 14.26% 15.80% 16.15% 17.59% 18.56%
Vertex Pharmaceuticals Inc. 19.02% 21.76% 22.41% 21.18% 21.22% 21.18% -5.99% -3.26% -3.07% -3.32% 21.67% 20.59% 21.01% 21.75% 22.59% 23.88% 25.12% 26.77% 22.47%

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
ROE = 100 × (Net income (loss) attributable to GileadQ3 2026 + Net income (loss) attributable to GileadQ2 2026 + Net income (loss) attributable to GileadQ1 2026 + Net income (loss) attributable to GileadQ4 2025) ÷ Total Gilead stockholders’ equity
= 100 × (2,429 + -10,496 + 2,021 + 2,183) ÷ 13,040 = -29.62%

2 Click competitor name to see calculations.


The Return on Equity (ROE) exhibits extreme volatility over the analyzed period, characterized by cycles of high profitability interrupted by sharp declines and deep negative turns corresponding to significant net losses.

Stability and Growth Phase (2022–2023)
Between March 2022 and December 2023, ROE remained consistently positive, fluctuating between 15.82% and 26.59%. This period was supported by steady net income and a gradual increase in stockholders' equity, which rose from 19.9 billion to 22.8 billion, reflecting a period of sustainable returns for shareholders.
First Profitability Contraction (2024)
A significant downturn occurred in the first quarter of 2024, precipitated by a net loss of 4.17 billion. This resulted in a sharp decrease in ROE to 2.77% and a corresponding reduction in total stockholders' equity to 17.5 billion. While net income returned to positive territory for the remainder of the year, ROE remained suppressed, reaching a low of 0.69% in September 2024.
Peak Performance and Subsequent Collapse (2025–2026)
From March 2025 through March 2026, a period of rapid expansion in efficiency is observed, with ROE climbing from 31.13% to a peak of 39.19%. This growth was driven by strong quarterly net income and a recovering equity base. However, this trend reversed abruptly in June 2026 following a substantial net loss of 10.5 billion, which caused ROE to plunge to -27.39%. This negative trajectory continued into September 2026, with ROE declining further to -29.62% as shareholders' equity remained significantly eroded at 13.04 billion.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Return on Assets (ROA)

Gilead Sciences Inc., ROA calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead 2,429 (10,496) 2,021 2,183 3,052 1,960 1,315 1,783 1,253 1,614 (4,170) 1,430 2,180 1,045 1,010 1,640 1,789 1,144 19
Total assets 51,408 49,362 56,278 59,023 58,533 55,721 56,434 58,995 54,525 53,579 56,292 62,125 62,373 62,337 61,876 63,171 62,557 62,870 63,080
Profitability Ratio
ROA1 -7.51% -6.56% 16.38% 14.42% 13.86% 11.33% 10.57% 0.81% 0.23% 1.97% 0.86% 9.12% 9.42% 8.80% 9.02% 7.27% 5.33% 6.58% 7.16%
Benchmarks
ROA, Competitors2
AbbVie Inc. 7.00% 4.67% 2.66% 3.15% 1.78% 2.74% 3.08% 3.17% 3.57% 3.76% 4.03% 3.61% 4.78% 6.42% 5.64% 8.53% 9.49% 8.83% 8.71%
Amgen Inc. 9.78% 9.14% 8.43% 8.51% 7.77% 7.53% 6.64% 4.45% 4.65% 3.44% 4.05% 6.91% 8.36% 8.84% 8.92% 10.06% 10.73% 11.09% 9.67%
Bristol-Myers Squibb Co. 10.41% 10.59% 8.41% 7.83% 6.23% 5.33% 5.86% -9.66% -7.75% -6.91% -6.21% 8.43% 9.08% 8.52% 7.75% 6.53% 6.80% 6.59% 6.07%
Danaher Corp. 4.64% 4.33% 4.42% 4.33% 4.38% 4.18% 4.76% 5.03% 4.83% 5.35% 5.28% 5.64% 6.74% 7.49% 8.15% 8.55% 8.35% 7.76% 7.74%
Eli Lilly & Co. 18.63% 18.77% 21.68% 18.35% 16.02% 13.67% 12.42% 13.45% 11.07% 10.22% 9.60% 8.19% 8.61% 11.85% 10.70% 12.62% 12.71% 12.09% 13.06%
Johnson & Johnson 8.15% 10.46% 10.47% 13.46% 13.03% 11.72% 11.26% 7.81% 8.24% 20.99% 22.37% 20.98% 20.85% 6.81% 6.49% 9.57% 10.94% 10.33% 11.12%
Merck & Co. Inc. 1.85% 2.44% 6.94% 13.34% 14.69% 13.96% 15.14% 14.62% 10.34% 12.20% 2.18% 0.34% 4.32% 2.98% 12.09% 13.30% 14.25% 15.48% 13.29%
Pfizer Inc. 1.97% 2.15% 3.61% 3.73% 4.71% 5.22% 3.79% 3.76% 1.94% -1.20% -0.14% 0.94% 4.87% 9.75% 14.85% 15.91% 15.32% 15.01% 13.58%
Regeneron Pharmaceuticals Inc. 10.85% 10.37% 10.82% 11.11% 11.40% 11.67% 11.98% 11.69% 12.43% 11.98% 11.22% 11.95% 12.41% 14.02% 13.91% 14.85% 19.40% 20.90% 30.11%
Thermo Fisher Scientific Inc. 6.19% 6.16% 6.05% 6.08% 6.38% 6.50% 6.58% 6.51% 6.11% 6.32% 6.21% 6.07% 6.12% 6.08% 6.36% 7.15% 7.77% 8.21% 8.20%
Vertex Pharmaceuticals Inc. 12.15% 16.06% 16.38% 15.42% 14.78% 15.13% -4.32% -2.38% -2.16% -2.43% 16.81% 15.92% 15.97% 16.54% 17.18% 18.30% 19.59% 20.50% 17.19%

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
ROA = 100 × (Net income (loss) attributable to GileadQ3 2026 + Net income (loss) attributable to GileadQ2 2026 + Net income (loss) attributable to GileadQ1 2026 + Net income (loss) attributable to GileadQ4 2025) ÷ Total assets
= 100 × (2,429 + -10,496 + 2,021 + 2,183) ÷ 51,408 = -7.51%

2 Click competitor name to see calculations.


The return on assets (ROA) for the analyzed period exhibits significant volatility, characterized by alternating phases of steady growth, sharp declines, and a substantial recovery before a final downturn. The overall trend indicates an inconsistent relationship between net income generation and asset utilization, with extreme fluctuations in profitability impacting the efficiency of the asset base.

Initial Stability and Growth Phase (2022–2023)
From March 2022 through December 2023, ROA remained relatively stable, fluctuating between 5.33% and 9.42%. During this period, total assets were maintained at a consistent level, generally between 62 billion and 63 billion US dollars. A gradual upward trajectory in ROA is observed throughout 2023, coinciding with net income peaks of 2.18 billion US dollars in September 2023.
First Period of Contraction (Early 2024)
A marked decline in ROA occurred in the first half of 2024, with values dropping to a low of 0.23% in September 2024. This compression was primarily driven by a significant net loss of 4.17 billion US dollars in March 2024, alongside a reduction in total assets to approximately 53.5 billion to 58.9 billion US dollars. The low ROA during this phase indicates a temporary inability to generate positive returns from the company's assets.
Expansion and Peak Efficiency (Mid 2024–Early 2026)
A strong recovery trend began in March 2025, with ROA climbing steadily from 10.57% to a peak of 16.38% by March 2026. This period represents the highest asset efficiency in the dataset. The improvement was fueled by a combination of rising net income, reaching 3.05 billion US dollars in June 2025, and a simultaneous contraction in the total asset base, which fell to 56.27 billion US dollars by March 2026.
Significant Volatility and Final Decline (Mid 2026–September 2026)
The period concludes with a severe reversal in profitability. In June 2026, a substantial net loss of 10.49 billion US dollars triggered a sharp drop in ROA to -6.56%, further declining to -7.51% by September 2026. Despite the asset base reaching its lowest point of 49.36 billion US dollars in June 2026, the magnitude of the losses overwhelmed any efficiency gains from the reduced asset size, resulting in negative returns on assets.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?